MedTrace Logo

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

NCT07232654 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-01

No results posted yet for this study

Summary

This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.

Conditions

  • LOCALLY ADVANCED CERVICAL CANCERS

Interventions

DRUG

Iparomlimab/Tuvonralimab

IV infusion

DRUG

Cisplatin

IV infusion

RADIATION

Brachytherapy and External Beam Radiotherapy

Radiation

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-11
Primary Completion
2027-11-30
Completion
2028-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07232654 on ClinicalTrials.gov